Monopar Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Monopar Therapeutics Inc. (MNPR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 3.27 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-12
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 2.75K shares, a 1.85% increase year-over-year.
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 520.00 shares, a 97.50% decline year-over-year.
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 18.50K shares.
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 5.82K shares, a 70.34% decline year-over-year.
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 47.85K shares, a 143.79% increase from fiscal 2024.
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 19.63K shares, a 128.98% increase from fiscal 2023.
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 8.57K shares, a 97.46% decline from fiscal 2022.
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 337.10K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 2.75K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | 3.27K shares 10-Q · filed 2026-08-12 | 21.77K shares derived: sum of 3 quarters · filed 2026-08-12 | 27.59K shares derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | 520.00 shares 10-Q · filed 2026-05-14 | 19.02K shares derived: sum of 2 quarters · filed 2026-05-14 | 24.84K shares derived: sum of 3 quarters · filed 2026-05-14 | 27.54K shares derived: sum of 4 quarters · filed 2026-05-14 | |
| 2025-12-31 | 18.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | 24.32K shares derived: sum of 2 quarters · filed 2026-03-27 | 27.02K shares derived: sum of 3 quarters · filed 2026-03-27 | 47.85K shares 10-K · filed 2026-03-27 | |
| 2025-09-30 | 5.82K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | 8.52K shares derived: sum of 2 quarters · filed 2025-11-13 | 29.35K shares 10-Q · filed 2025-11-13 | 29.35K shares derived: sum of 4 quarters · filed 2026-03-27 | |
| 2025-06-30 | 2.70K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 23.53K shares 10-Q · filed 2025-08-12 | 23.53K shares derived: sum of 3 quarters · filed 2026-03-27 | 43.16K shares derived: sum of 4 quarters · filed 2026-03-27 | |
| 2025-03-31 | 20.83K shares 10-Q · filed 2025-05-13 | 20.83K shares derived: sum of 2 quarters · filed 2026-03-27 | 40.46K shares derived: sum of 3 quarters · filed 2026-03-27 | 40.46K shares derived: sum of 4 quarters · filed 2026-03-27 | |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | 19.63K shares derived: sum of 2 quarters · filed 2026-03-27 | 19.63K shares derived: sum of 3 quarters · filed 2026-03-27 | 19.63K shares 10-K · filed 2026-03-27 | |
| 2024-09-30 | 19.63K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | 19.63K shares derived: sum of 2 quarters · filed 2024-11-08 | 19.63K shares 10-Q · filed 2024-11-08 | -14.65K shares derived: sum of 4 quarters · filed 2025-03-31 | |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | 0.00 shares 10-Q · filed 2024-08-09 | -34.28K shares derived: sum of 3 quarters · filed 2025-03-31 | -29.28K shares derived: sum of 4 quarters · filed 2025-03-31 | |
| 2024-03-31 | 0.00 shares 10-Q · filed 2024-05-09 | -34.28K shares derived: sum of 2 quarters · filed 2025-03-31 | -29.28K shares derived: sum of 3 quarters · filed 2025-03-31 | ||
| 2023-12-31 | -34.28K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -29.28K shares derived: sum of 2 quarters · filed 2025-03-31 | 8.57K shares 10-K · filed 2025-03-31 | 42.85K shares 10-K · filed 2024-03-28 | |
| 2023-09-30 | 5.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 42.85K shares 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | 37.85K shares 10-Q · filed 2023-08-10 | ||||
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | 131.17K shares derived: sum of 2 quarters · filed 2024-03-28 | 305.15K shares derived: sum of 3 quarters · filed 2024-03-28 | 337.10K shares 10-K · filed 2024-03-28 | |
| 2022-09-30 | 131.17K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 305.15K shares derived: sum of 2 quarters · filed 2022-11-10 | 337.10K shares 10-Q · filed 2022-11-10 | ||
| 2022-06-30 | 173.98K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 205.93K shares 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | 31.95K shares 10-Q · filed 2022-05-12 | ||||
| 2021-12-31 | 115.15K shares 10-Q · filed 2022-11-10 | ||||
| 2021-03-31 | 3.34K shares 10-Q · filed 2021-05-13 | 6.59K shares derived: sum of 2 quarters · filed 2021-05-13 | 6.59K shares derived: sum of 3 quarters · filed 2021-05-13 | 6.59K shares derived: sum of 4 quarters · filed 2021-05-13 | |
| 2020-12-31 | 3.24K shares derived: 10-Q 12 month − 10-Q 9 month · filed 2021-05-13 | 3.24K shares derived: sum of 2 quarters · filed 2021-05-13 | 3.24K shares derived: sum of 3 quarters · filed 2021-05-13 | 3.24K shares 10-Q · filed 2021-05-13 | |
| 2020-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | 0.00 shares derived: sum of 2 quarters · filed 2020-11-12 | 0.00 shares 10-Q · filed 2020-11-12 | 0.00 shares derived: sum of 4 quarters · filed 2020-11-12 | |
| 2020-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | 0.00 shares 10-Q · filed 2020-08-06 | 0.00 shares derived: sum of 3 quarters · filed 2020-11-12 | 0.00 shares derived: sum of 4 quarters · filed 2020-11-12 | |
| 2020-03-31 | 0.00 shares 10-Q · filed 2020-05-07 | 0.00 shares derived: sum of 2 quarters · filed 2020-11-12 | 0.00 shares derived: sum of 3 quarters · filed 2020-11-12 | 0.00 shares derived: sum of 4 quarters · filed 2020-11-12 | |
| 2019-12-31 | 0.00 shares derived: 10-Q 12 month − 10-Q 9 month · filed 2020-11-12 | 0.00 shares derived: sum of 2 quarters · filed 2020-11-12 | 0.00 shares derived: sum of 3 quarters · filed 2020-11-12 | 0.00 shares 10-Q · filed 2020-11-12 | |
| 2019-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | 0.00 shares derived: sum of 2 quarters · filed 2019-11-12 | 0.00 shares 10-Q · filed 2019-11-12 | 0.00 shares derived: sum of 4 quarters · filed 2020-03-27 | |
| 2019-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | 0.00 shares 10-Q · filed 2019-08-08 | 0.00 shares derived: sum of 3 quarters · filed 2020-03-27 | 5.83K shares derived: sum of 4 quarters · filed 2020-03-27 | |
| 2019-03-31 | 0.00 shares 10-Q · filed 2019-05-10 | 0.00 shares derived: sum of 2 quarters · filed 2020-03-27 | 5.83K shares derived: sum of 3 quarters · filed 2020-03-27 | 40.00K shares derived: sum of 4 quarters · filed 2020-03-27 | |
| 2018-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | 5.83K shares derived: sum of 2 quarters · filed 2020-03-27 | 40.00K shares derived: sum of 3 quarters · filed 2020-03-27 | 40.00K shares 10-K · filed 2020-03-27 | |
| 2018-09-30 | 5.83K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | 40.00K shares derived: sum of 2 quarters · filed 2018-11-09 | 40.00K shares 10-Q · filed 2018-11-09 | ||
| 2018-06-30 | 34.17K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | 34.17K shares 10-Q · filed 2018-08-09 | |||
| 2018-03-31 | 0.00 shares 10-Q · filed 2018-05-11 | ||||
| 2017-12-31 | 0.00 shares 10-K · filed 2019-02-26 | ||||
| 2017-03-31 | 0.00 shares 10-Q · filed 2018-05-11 | ||||
| 2016-12-31 | 0.00 shares 10-K · filed 2018-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |